ClinicalTrials.gg
Not yet recruitingNCT07422051Updated Feb 19, 2026

Erythrodiol in Pomace Olive Oil as a Protective Agent Against Atherosclerosis

A Phase 2 interventional study of Low erythrodiol dose and Medium erythrodiol dose in Atherosclerosis Cardiovascular Disease, sponsored by Spanish National Research Council. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Spanish National Research Council · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Atherosclerosis with a site in Spain — 10 open to participants now, 25 under way, 12 of them phase 3. Atherosclerosis · Spain.

Planned enrollment
41st of 41
22 · median 969
Started
2026
with 4 others
Phase 2
6 of 61
2 open now
Primary completion
2026-06
later than 3 of 24 live
Registered
56th of 61
by date

Among the 61 studies in Atherosclerosis with a site in Spain, this one is the 41st largest by planned enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 3 of the 24 other live ones, and was the 56th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

10 of the 61 studies in Atherosclerosis with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Atherosclerosis with a site in Spain, or all of them as a file.
02

Study summary

The goal of this postprandial clinical trial is to learn whether erythrodiol, a triterpene naturally present in pomace olive oil, can modulate the cell foam formation, ine of the first steps in atherosclerosis. The main questions it aims to answer are:

Is erythrodiol bioavailable in humans when administered as pomace olive oil? Does acute erythrodiol intake reduce postprandial triglyceride excursions after a high-fat meal? Does erythrodiol reduce the intake of postprandial triglyceride-rich lipoproteins by macrophages?

Researchers will compare participants receiving test meals enriched with different concentrations of erythrodiol (low, medium, high) to see if the intervention leads to improved postprandial metabolic and vascular responses.

Participants will:

Attend the research facility after an overnight fast. Consume a high-fat test meal enriched with a different doses of erythrodiol

Undergo serial postprandial assessments over several hours, including:

Blood sampling for lipids, glucose, inflammatory markers, and oxidative stress biomarkers Monitoring of subjective tolerability and adverse events

Read the detailed description

The present project builds on previous studies in which we suggested that erythrodiol, a bioactive component of pomace olive oil, is capable of helping prevent cardiovascular diseases when administered as part of pomace oil, through the inhibition of atherosclerosis development.

A total of 22 adult volunteers, both women and men (18-40 years old), healthy and of normal weight, will be selected. Participants will be recruited in two phases.

In the first phase, recruitment will take place at Pablo de Olavide University. Inclusion criteria for this phase include: age between 18 and 40 years; body mass index (BMI) between 18.5 and 24.9 kg/m²; ability to provide informed voluntary consent; and willingness to comply with all study procedures. Candidates will be excluded if, at the time of recruitment, they exhibit any of the following: presence of any type of pathology (digestive, metabolic, endocrine, infectious, neoplastic, etc.) or food-related allergies or intolerances. Individuals taking any type of medication-except contraceptives-will also be excluded, as well as pregnant or breastfeeding women, and anyone who has participated in a clinical trial involving an investigational product within the past 60 days or is currently enrolled in a clinical trial. Furthermore, any person with a physical or intellectual limitation that, in the investigator's opinion, could prevent adherence to and completion of the protocol will be excluded. In this phase, only clinical history, age, weight, and height data will be collected.

In the second phase, only those subjects whose complete biochemical and hematological analyses produce results within normal ranges will be included in the study.

At the Virgen del Rocío Hospital (Seville), and after a 12-hour fast, three experiments will be conducted. In each of them, participants will be administered pomace olive oil containing different concentrations (low, medium, or high) of erythrodiol, the protective agent, in an amount of 50 g on each occasion. On the study day, blood samples will be taken (between 6 and 24 mL per draw and 90 mL total), 15 minutes before (baseline) and every hour for 6 hours after ingestion of a meal rich in the corresponding pomace oil. The meal will be accompanied by coffee (black, without sugar) or skimmed milk and whole-grain toast (3 slices). The consumption of these foods carries no health risk.

Venous access will be obtained by puncture with an Abbocath® catheter fitted with a Smartsite™ valve (Ivac®, Spec-Sets®) and a Vacutainer® system for sterile Hemogard® tubes with a silicone separator. This procedure involves only the risks inherent to simple blood sampling.

Part of the collected samples will be processed at the Clinical Analysis Laboratory Service of the Virgen del Rocío University Hospital for biochemical analysis, while another portion will be sent to the Instituto de la Grasa-CSIC.

In addition to these analyses, participants will undergo simple anthropometric measurements (weight, height, hip and waist circumference) as well as blood pressure assessment.

This procedure will be repeated after four weeks with a second oil, and four weeks later with the third one, so that all participants will have consumed all three oils.

03

Conditions studied

  • Atherosclerosis Cardiovascular Disease

Browse trials for

Keywords

  • Randomized postprandial crossover trial
  • Erythrodiol
  • Pomace olive oil
  • Atherosclerosis
  • Macrophages
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 40 years.
  • Male or female volunteers.
  • Healthy individuals with no diagnosed diseases.
  • Normal-weight participants with a (BMI) between 18.5 and 24.9 kg/m².
  • Ability to provide voluntary .
  • Willingness to comply with all study procedures.
  • Availability to participate in the two-phase selection process, including initial screening and subsequent laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • Presence of any type of disease, including digestive, metabolic, endocrine, infectious, neoplastic conditions, or associated allergies and food intolerances.
  • Current use of any medication, except hormonal .
  • Pregnant or breastfeeding women.
  • Participation in a clinical trial with an product within the last 60 days, or current enrolment in a clinical trial.
  • Any physical or intellectual limitation that, in the opinion of the investigator, could impede following or completing the study protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
22 participants (estimated)

Study arms

  • Active comparator
    Low erythrodiol

    Other: Low erythrodiol dose

  • Active comparator
    Medium erythrodiol

    Other: Medium erythrodiol dose

  • Active comparator
    High erythrodiol

    Other: High erythrodiol dose

Interventions

  • OtherLow erythrodiol dose

    Low erythrodiol dose

  • OtherMedium erythrodiol dose

    Medium erythrodiol dose

  • OtherHigh erythrodiol dose

    High erythrodiol dose

06

What researchers measure

Primary outcomes

  1. Plasma erythrodiol concentration

    Time frame: 4 months since the last intervention session

Secondary outcomes

  1. Plasma triglyceride concentration

    Time frame: 4 months since the last intervention session

  2. Inflammation marker concentration in plasma

    Time frame: 4 months since the last intervention session

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Jun 2026, 4 months later.

Of 46 phase 2 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 19, 2026
StartEst.
Feb 21, 2026
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07422051
Lead sponsor
Spanish National Research Council
Responsible party
Javier Sanchez Perona (Scientific Researcher, Spanish National Research Council) — Principal investigator
First posted
Feb 19, 2026
Start date
Feb 21, 2026 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Feb 19, 2026

Study contacts

Javier Perona S. Perona, PhD
Contact
perona@ig.csic.es
34954611550

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion